Antibodies
29 August 2017
New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels29 August 2017
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab28 August 2017
GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis28 August 2017
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk28 August 2017
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma26 August 2017
Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection25 August 2017
IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union24 August 2017
Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US24 August 2017
Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma24 August 2017
Chugai’s Emicizumab Receives Priority Review Designation by FDA for Hemophilia A with Inhibitors23 August 2017
Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer22 August 2017
Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody22 August 2017
Takeda Submits a New Drug Application for Vedolizumab for the Treatment of Moderately to Severely Ulcerative Colitis in JapanNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports